Trends in the global funding and activity of cancer research

Cancer research has carved an astonishing trajectory giving rise to a multi billion euro global network covering most domains of science and including all manner of research funders from industry to government and philanthropic funders. We have estimated that in 2004/2005 the global spend on cancer research was 14,030 million euros, with the USA, dominated by the NCI (c. 83%) accounting for the largest absolute spend. This is between 2 and 3 times the level of per capita spend compared to EU‐15 and Europe, respectively. In Europe, the UK is at comparable levels of spend compared to the USA. Funding for cancer research in Europe is split almost 50:50 between philanthropic and governmental sources. Cancer research productivity in terms of outputs (publications) is slightly greater in Europe compared to the USA with an increasing trend towards more applied (clinical) outputs. Both the USA and Europe have equally strong industry‐supported output levels.

[1]  J. H. Fujimura.  The Molecular Biological Bandwagon in Cancer Research: Where Social Worlds Meet , 1988 .

[2]  Philippe Larédo,et al.  The networks promoted by the framework programme and the questions they raise about its formulation and implementation , 1998 .

[3]  R. Sullivan,et al.  The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK. , 2007, European journal of cancer.

[4]  M. Cheng.  Cancer research funding in Asia , 2007, Molecular oncology.

[5]  Lyal B. Harris.  November , 1890, The Hospital.

[6]  W. Hamilton.  The genetical evolution of social behaviour. I. , 1964, Journal of theoretical biology.

[7]  Bruce Neal,et al.  Priority medicines for Europe and the world , 2004 .

[8]  M. Hartmann,et al.  The Clinical Trials Directive: How Is It Affecting Europe's Noncommercial Research? , 2006, PLoS clinical trials.

[9]  W. L. Sumner.  The Two Cultures and the Scientific Revolution , 1959, Nature.

[10]  J. Niederhuber.  A look inside the National Cancer Institute budget process: implications for 2007 and beyond. , 2007, Cancer research.

[11]  Tianhong Li,et al.  Sulindac suppressed beta-catenin expression in human malignant cell lines , 2007 .

[12]  Epstein,et al.  The politics of cancer , 2000, JAMA.

[13]  S. Jungbluth,et al.  Europe combating cancer: The European Union's commitment to cancer research in the 6th Framework Programme , 2007, Molecular oncology.

[14]  R. Trivers.  The Evolution of Reciprocal Altruism , 1971, The Quarterly Review of Biology.

[15]  D. Mowery.  The changing structure of the US national innovation system: implications for international conflict and cooperation in R&D policy , 1998 .

[16]  Richard Sullivan,et al.  A Survey of Public Funding of Cancer Research in the European Union , 2006, PLoS medicine.

[17]  Keith Pavitt,et al.  THE INEVITABLE LIMITS OF EU R&D FUNDING , 1998 .

[18]  P. Butow,et al.  Beyond scientific rigour: funding cancer research of public value. , 2007, Health policy.

[19]  Daryl E. Chubin,et al.  The politics of cancer , 1978 .

[20]  Edward E. Jones,et al.  The Politics of Pure Science. , 1969 .

[21]  Grant Lewison,et al.  The classification of biomedical journals by research level , 2004, Scientometrics.

[22]  N. Humphrey.  Varieties of altruism : And the common ground between them , 1997 .

[23]  G. Lewison,et al.  Mapping the emergence and development of translational cancer research. , 2006, European journal of cancer.